Article
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Cancer discovery - 1 Dec 2020
Wang Guangchuan, Chow Ryan D, Zhu Lvyun, Bai Zhigang, Ye Lupeng, Zhang Feifei, Renauer Paul A, Dong Matthew B, Dai Xiaoyun, Zhang Xiaoya, Du Yaying, Cheng Yujing, Niu Leilei, Chu Zhiyuan, Kim Kristin, Liao Cun, Clark Paul, Errami Youssef, Chen Sidi
Abstract excerpt
Immune checkpoint blockade (ICB) has shown remarkable clinical efficacy in several cancer types. However, only a fraction of patients will respond to ICB. Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMM) in ICB settings, and identified KMT2D as a major modulator of ICB response across multiple cancer types. KMT2D encodes a histone H3K4...
Topics
Join the communities discussing this publication.